Introduction Welcome to the UCB Newsroom, your source for the latest updates, press releases, and stories that showcase our commitment to advancing science and improving patient lives.Stay informed about our recent breakthroughs, partnerships, and innovations through our features and news updates. Latest stories Story 17 Sep 2025 Driving progress for people living with dermatological conditions at EADV 2025 Read More Story 9 Sep 2025 Raising Awareness, Building Hope: Cultivating Support and Solutions for the TK2d Community Read More Story 29 Aug 2025 Navigating the Barriers to Identifying and Treating Developmental and Epileptic Encephalopathies in... Read More Latest press releases The press releases are intended for media and financial analysts Press release 17 Sep 2025 BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained... Read More Press release 17 Sep 2025 BIMZELX[®][▼] (bimekizumab) data in moderate-to-severe plaque psoriasis at EADV showed four-year... Read More Press release 29 Aug 2025 UCB presents latest research and clinical advancement across leading epilepsy portfolio at... Read More Interested in more? Access our media image selection or contact us for particular requests.The UCB media relations team responds to calls and emails from professional journalists only. View all downloadable resources Contact us
Story 17 Sep 2025 Driving progress for people living with dermatological conditions at EADV 2025 Read More
Story 9 Sep 2025 Raising Awareness, Building Hope: Cultivating Support and Solutions for the TK2d Community Read More
Story 29 Aug 2025 Navigating the Barriers to Identifying and Treating Developmental and Epileptic Encephalopathies in... Read More
Press release 17 Sep 2025 BIMZELX[®]▼(bimekizumab) new three-year data in hidradenitis suppurativa at EADV showed sustained... Read More
Press release 17 Sep 2025 BIMZELX[®][▼] (bimekizumab) data in moderate-to-severe plaque psoriasis at EADV showed four-year... Read More
Press release 29 Aug 2025 UCB presents latest research and clinical advancement across leading epilepsy portfolio at... Read More
